venetoclax,ibrutinib
abbvie,janssen,roche
['leukemia', 'imbruvica', 'glow', 'venetoclax', 'janssen']
#janssen reported new results from the phase 3 glow study of fixed-duration treatment with #imbruvica (#ibrutinib) plus #venetoclax demonstrate robust efficacy with previously untreated #chroniclymphocyticleukemia #ash22 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.